Clinical Neurology and Neurosurgery | 2021
Neuroaspis PLP10™, a nutritional formula rich in omega-3 and omega-6 fatty acids with antioxidant vitamins including gamma-tocopherol in early Parkinson’s disease: A randomized, double-blind, placebo-controlled trial
Abstract
In the present study, we investigated whether Neuroaspis PLP10™, a well-designed intervention, rich in omega-3 (n-3) and omega-6 (n-6) polyunsaturated fatty acids (PUFAs) with specific antioxidant vitamins, may exert positive action in the improvement of Parkinson s disease symptoms and perhaps delay the progression of the disease when used as an adjuvant to the conventional treatment. Forty patients were randomized 1:1 to receive either 20\xa0ml dose, once daily, of control (pure virgin olive oil) or Neuroaspis PLP 10™, a formula containing a mixture of omega-3 (810\xa0mg Eicosapentaenoic acid and 4140\xa0mg Docosahexaenoic acid) and omega-6 fatty acids (1800\xa0mg\xa0gamma-Linolenic acid and 3150\xa0mg Linoleic acid) (1:1 w/w), with 0.6\xa0mg vitamin A, vitamin E (22\xa0mg) plus pure gamma (γ)-tocopherol (760\xa0mg), for a total of 30 months in a randomized double-blind, placebo-controlled trial. Participants completed assessments based on the Hoehn and Yahr Staging Scale of Parkinson s Disease (HY scale) and the Unified Parkinson s Disease Rating Scale (UPDRS) III. Overall, for this small sample size clinical trial, Neuroaspis PLP10™ supplementation as an adjuvant treatment for 30 months in PD patients significantly delayed disease progression according to UPDRS (p\xa0≤\xa00.05) Vs placebo.